www.newsmax.com
Lilly's Zepbound Tops Wegovy for Weight Loss in Trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines. In the 751-person trial, Zepbound helped patients lose...